Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,501 to 2,520 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) vs Enoxaparin 30 mg Twice a Day (Bid): serious adverse events | 106 of 1,526 131 of 1,508 | -1.7 points -3.7 to 0.2 | 3,034 | NCT00362232 Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. |
| Early Intervention vs Delayed Intervention: First Occurrence of Any Component of the Composite of Death, MI, or Refractory Ischemia | 151 of 1,593 186 of 1,438 | -3.5 points -5.7 to -1.2 | 3,031 | NCT00552513 Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes |
| Early Intervention vs Delayed Intervention: Composite of Death, Myocardial (re-) Infarction, or Stroke | 153 of 1,593 163 of 1,438 | -1.7 points -3.9 to 0.4 | 3,031 | NCT00552513 Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes |
| Arm I (Aspirin) vs Arm II (Placebo): deaths from any cause | 48 of 1,511 43 of 1,510 | 0.3 points -0.9 to 1.6 | 3,021 | NCT02927249 Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy |
| Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 vs Group 2: Placebo: Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 30 Visits (PP Set) | 71 of 1,525 67 of 1,494 | 0.2 points -1.3 to 1.7 | 3,019 | NCT03964415 A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals |
| Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 vs Group 2: Placebo: Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set) | 65 of 1,525 58 of 1,494 | 0.4 points -1.0 to 1.8 | 3,019 | NCT03964415 A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals |
| Rivaroxaban 2.5 mg Twice Daily (BID) vs Acetylsalicylic Acid 100 mg Once Daily (OD): serious adverse events | 125 of 1,510 138 of 1,506 | -0.9 points -2.9 to 1.1 | 3,016 | NCT02293395 A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome |
| GSK3390107A Group vs Placebo+GSK3390107A Group: Number of Subjects With Serious Adverse Events (SAEs) | 11 of 1,509 18 of 1,504 | -0.5 points -1.2 to 0.3 | 3,013 | NCT02485301 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults |
| GSK3390107A Group vs Placebo+GSK3390107A Group: deaths from any cause | 1 of 1,509 2 of 1,504 | -0.1 points -0.4 to 0.3 | 3,013 | NCT02485301 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults |
| GSK3390107A Group vs Placebo+GSK3390107A Group: serious adverse events | 11 of 1,509 18 of 1,504 | -0.5 points -1.2 to 0.3 | 3,013 | NCT02485301 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults |
| Daprodustat vs Darbepoetin Alfa: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52) | 1,167 of 1,491 1,063 of 1,520 | 8.3 points 5.2 to 11.4 | 3,011 | NCT02876835 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Emergency Room (ER) Visits for Any Cause | 298 of 2,005 155 of 1,006 | -0.5 points -3.3 to 2.1 | 3,011 | NCT06291831 A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Hospitalization for Any Cause | 137 of 2,005 123 of 1,006 | -5.4 points -7.8 to -3.2 | 3,011 | NCT06291831 A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants Who Used Invasive Mechanical Ventilation (IMV) | 0 of 2,005 1 of 1,006 | -0.1 points -0.6 to 0.1 | 3,011 | NCT06291831 A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Supplemental Oxygen Usage | 21 of 2,005 11 of 1,006 | -0.0 points -1.0 to 0.7 | 3,011 | NCT06291831 A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With at Least 1 Pre-existing Comorbidities | 1,709 of 2,005 920 of 1,006 | -6.2 points -8.5 to -3.8 | 3,011 | NCT06291831 A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause | 3 of 2,005 1 of 1,006 | 0.1 points -0.4 to 0.4 | 3,011 | NCT06291831 A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. |
| Apixiban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo: serious adverse events | 72 of 1,501 88 of 1,508 | -1.0 points -2.7 to 0.6 | 3,009 | NCT00452530 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery |
| Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Ischemic Target Lesion Revascularization | 98 of 2,257 54 of 749 | -2.9 points -5.1 to -1.0 | 3,006 | NCT00433966 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
| Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis | 181 of 2,257 59 of 749 | 0.1 points -2.3 to 2.2 | 3,006 | NCT00433966 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
Code
curl "https://conductscience.org/api/comparisons/v1?page=126"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=126
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00362232-sae",
"title": "Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) vs Enoxaparin 30 mg Twice a Day (Bid): serious adverse events",
"summary": "106 of 1526 against 131 of 1508; risk difference -1.7 points, 95% interval -3.7 to 0.2; NCT00362232, Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.",
"record": "/library/comparisons/NCT00362232-sae",
"nct_id": "NCT00362232",
"kind": "serious-adverse-events",
"participants": 3034,
"risk_difference": {
"value": -0.01740737908090012,
"lower": -0.036659503884868605,
"upper": 0.001727918840074432
},
"group_1": "106 of 1,526",
"group_2": "131 of 1,508",
"difference": "-1.7 points",
"interval": "-3.7 to 0.2",
"trial_title": "Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement."
},
{
"id": "NCT00552513-0c3f1395",
"title": "Early Intervention vs Delayed Intervention: First Occurrence of Any Component of the Composite of Death, MI, or Refractory Ischemia",
"summary": "151 of 1593 against 186 of 1438; risk difference -3.5 points, 95% interval -5.7 to -1.2; NCT00552513, Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes",
"record": "/library/comparisons/NCT00552513-0c3f1395",
"nct_id": "NCT00552513",
"kind": "outcome",
"participants": 3031,
"risk_difference": {
"value": -0.03455660936625553,
"lower": -0.05728322127511208,
"upper": -0.012104102117430713
},
"group_1": "151 of 1,593",
"group_2": "186 of 1,438",
"difference": "-3.5 points",
"interval": "-5.7 to -1.2",
"trial_title": "Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=127",
"request_id": "km8eBBvyBlv8IQwD"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant